comparemela.com

Latest Breaking News On - Cancer eighth edition - Page 1 : comparemela.com

New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis

In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy had 50% higher.

United statesSaraht arronCastle biosciencesCastle biosciences incNational comprehensive cancer networkAmerican joint committee on cancer eighth editionInternational journal of radiation oncologyInternational journalRadiation oncologyRed journalPeninsula dermatologyAmerican joint committeeCancer eighth editionMypath melanoma

Study Data from Castle Biosciences Collaboration with the National Cancer Institute s SEER Program Registries Published in JCO Precision Oncology

Data shows testing with DecisionDx®-Melanoma provided significant prognostic information regarding survival outcomes

United statesMatthew goldbergDerek maetzoldCastle biosciencesCastle biosciences incProgram registriesAmerican joint committee on cancer eighth editionSecurities exchangeAmerican joint committeeCancer eighth editionDecisiondx melanomaMypath melanomaSecurities actSecurities exchange actQuarterly reportGene expression profile testing

vimarsana © 2020. All Rights Reserved.